# US 9,427,002 B2 · Isoflavone compositions for reducing accumulation of body fat in male mammals, and methods for their use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,427,002 B2
- Document ID: US9427002B2
- Status: Granted
- Kind: B2
- Application number: 13/365,868
- Filed: 2012-02-03
- Published: 2012-08-09
- Granted: 2016-08-30
- Earliest claimed: 2005-11-02
- Assignees: Nestec S.A.
- Applicants: Yuanlong Pan
- Inventors: Yuanlong Pan
- Web page: https://patentgrep.com/patent/US9427002B2

## CPC

- A23K 20/10: Organic substances
- A23K 20/111: Aromatic compounds
- A23K 50/40: for carnivorous animals, e.g. cats or dogs
- A23K 50/60: for weanlings
- A23L 33/10: using additives (addition of substantially indigestible substances A23L33/21)
- A23L 33/105: Plant extracts, their artificial duplicates or their derivatives
- A61K 31/353: 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A23K: FODDER
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Edible compositions useful for weight management in male animals are disclosed. The compositions comprise one or more isoflavones or isoflavone metabolites and are particularly useful for reducing or preventing the accumulation of body fat. Also disclosed are methods useful for weight management in an animal utilizing compositions comprising one or more isoflavones. The compositions and methods are particularly useful for the reduction or prevention of body fat accumulation during periods of excess caloric intake, and preferably have a sparing effect on lean body mass.

## Claims

### Claim 1

A method for reducing fat accumulation in a canine consuming calories in excess of its minimum daily requirement, the method comprising identifying a canine, determining that the canine is consuming calories in excess of its minimum daily requirement, and providing to the canine on a regular basis a comestible composition comprising one or more isoflavones that metabolize to equol in an amount effective for reducing deposition of subcutaneous or intramuscular fat in the body of the canine.

### Claim 2 (depends on 1)

The method of claim 1, wherein the one or more isoflavones are from soy bean.

### Claim 3 (depends on 1)

The method of claim 1, wherein the comestible composition is a pet food, or a food supplement to be taken directly or added to a pet food, or to animal feed.

### Claim 4 (depends on 1)

The method of claim 1, wherein the canine is a male canine.

### Claim 5 (depends on 1)

The method of claim 1, wherein the canine is a puppy.

### Claim 6 (depends on 1)

The method of claim 1, wherein the composition is provided by administering to the canine on a daily basis.

### Claim 7 (depends on 1)

The method of claim 1, wherein the canine has not been neutered and is not post-andropausal.

### Claim 8 (depends on 7)

The method of claim 7, further comprising the step of determining that the canine is beyond the mid-point of the life expectancy for its species or breed.

### Claim 9 (depends on 1)

The method of claim 1, further comprising determining that the canine has been neutered; or is post-andropausal; or has reduced circulating estradiol concentrations relative to a healthy, nonobese male animal of the same species or breed; or has reduced ability to convert testosterone into estradiol relative to a healthy, nonobese male animal of the same species or breed; or has reduced aromatase activity relative to a healthy, nonobese male animal of the same species or breed.

### Claim 10 (depends on 9)

The method of claim 9, further comprising the step of determining that the circulating estradiol of the canine is less than about 80% of a healthy, nonobese male animal of the same species or breed.

### Claim 11 (depends on 9)

The method of claim 9, further comprising the step of determining that the circulating estradiol of the canine is less than about 50% of a healthy, nonobese male animal of the same species or breed.

### Claim 12 (depends on 9)

The method of claim 9, further comprising the step of determining that the circulating estradiol of the canine is less than about 20% of a healthy, nonobese male animal of the same species or breed.

### Claim 13 (depends on 9)

The method of claim 9, further comprising the step of determining that the circulating estradiol of the canine is less than about 10% of a healthy, nonobese animal of the same species or breed.

### Claim 14 (depends on 1)

The method of claim 1, wherein the comestible composition is provided to the canine before it reaches a normal adult body weight.